Innovative mRNA CAR Therapy MT-303 Under Study for Liver Cancer
MT-303, a novel GPC3-targeting mRNA/lipid nanoparticle chimeric antigen receptor therapy, enhances cytokine-driven immune response and tumor cytotoxicity.
Read More
Cancer Research Across Continents: Fujiwara’s Path From Japan to the US
In this episode of Emerging Experts, Yu Fujiwara, MD, shares his journey from Japan to the United States and his path to becoming a specialist in hematology and oncology.
Listen
FDA Grants NX-5948 Fast Track Designation in R/R Waldenström Macroglobulinemia
The FDA granted fast track designation to NX-5948 for treating relapsed/refractory Waldenström macroglobulinemia after 2 or more lines of therapy, including a BTK inhibitor.
LaPelusa’s Journey in the Dynamic Field of GI Oncology
In this episode of Emerging Experts, Michael LaPelusa, MD, shares his insights, experiences, and passion for cancer research, particularly in the realm of gastrointestinal cancers.
FDA Issues CRL for SC Amivantamab BLA in EGFR+ NSCLC
The FDA issued a complete response letter for the BLA submission of subcutaneous amivantamab for EGFR-mutated NSCLC, citing manufacturing inspection issues, but confirming no need for additional clinical trials.
Standard Belzutifan Dose Equally Effective as Higher Dose in ccRCC
In an interview with Targeted Oncology, Jaime Merchan, MD, delved into data from the LITESPARK-013 trial evaluating belzutifan for advanced clear cell renal cell carcinoma treatment.
